Search research articles
Contact Us
Filters
Showing results (451-460 of 455) with videos related to
Page
of 46
Sort By:
You have reached the last page of results.
This site can display upto 455 results.
Epigenetics
|
September 28, 2013
The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns
Ivana Türbachova, Tim Schwachula, Ines Vasconcelos, et al.
The Lancet. Oncology
|
April 20, 2020
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
Jacobus Pfisterer, Catherine M Shannon, Klaus Baumann, et al.
Cancers
|
January 21, 2022
Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study
Linn Woelber, Monika Hampl, Christine Zu Eulenburg, et al.
Gynecologic Oncology
|
July 16, 2025
Risk for non-sentinel metastases in the contralateral groin in patients with a unilateral positive sentinel lymph node in primary vulvar cancer- a subgroup analysis of the AGO-VOP.2 QS Vulva Study
Anna Jaeger, Monika Hampl, Katharina Prieske, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 20, 2020
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)
Aline Talhouk, Joshy George, Chen Wang, et al.
Page
of 46
Search research articles
Search
Showing results (451-460 of 455) with videos related to
Sort By:
Page
of 46
You have reached the last page of results.
This site can display upto 455 results.
Epigenetics
|
September 28, 2013
The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns
Ivana Türbachova, Tim Schwachula, Ines Vasconcelos, et al.
The Lancet. Oncology
|
April 20, 2020
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
Jacobus Pfisterer, Catherine M Shannon, Klaus Baumann, et al.
Cancers
|
January 21, 2022
Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study
Linn Woelber, Monika Hampl, Christine Zu Eulenburg, et al.
Gynecologic Oncology
|
July 16, 2025
Risk for non-sentinel metastases in the contralateral groin in patients with a unilateral positive sentinel lymph node in primary vulvar cancer- a subgroup analysis of the AGO-VOP.2 QS Vulva Study
Anna Jaeger, Monika Hampl, Katharina Prieske, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 20, 2020
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)
Aline Talhouk, Joshy George, Chen Wang, et al.
Page
of 46